These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12964175)

  • 41. Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
    Hertzberg MA; Feldman ME; Beckham JC; Moore SD; Davidson JR
    Ann Clin Psychiatry; 2002 Dec; 14(4):215-21. PubMed ID: 12630657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New indications for antidepressive agents. Now also in anxiety disorders and premenstrual syndrome?].
    Hochstrasser B
    MMW Fortschr Med; 2000 Dec; 142(49-50):41-4. PubMed ID: 11190938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response of patients in mixed state of anxiety and depression to low dose sulpiride.
    Kato K
    Igaku Kenkyu; 1993 Feb; 63(1):15-9. PubMed ID: 8328259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone.
    Agelink MW; Majewski T; Wurthmann C; Postert T; Linka T; Rotterdam S; Klieser E
    J Affect Disord; 2001 Feb; 62(3):187-98. PubMed ID: 11223106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder.
    Hung CI; Liu CY; Chen CY; Yang CH; Wang SJ
    J Headache Pain; 2014 Nov; 15(1):73. PubMed ID: 25382691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defining anxious depression in later life: a scaring heterogeneity in results.
    van der Veen DC; Comijs HC; van Zelst WH; Schoevers RA; Oude Voshaar RC
    Am J Geriatr Psychiatry; 2014 Nov; 22(11):1375-8. PubMed ID: 24703569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
    Hirschfeld RM; Dunner DL; Keitner G; Klein DN; Koran LM; Kornstein SG; Markowitz JC; Miller I; Nemeroff CB; Ninan PT; Rush AJ; Schatzberg AF; Thase ME; Trivedi MH; Borian FE; Crits-Christoph P; Keller MB
    Biol Psychiatry; 2002 Jan; 51(2):123-33. PubMed ID: 11822991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study.
    Tribó MJ; Andión O; Ros S; Gilaberte M; Gallardo F; Toll A; Ferrán M; Bulbena A; Pujol RM; Baños JE
    Dermatology; 2008; 216(1):24-30. PubMed ID: 18032895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New approaches in the chemotherapy of depressive conditions using Anafranil].
    Dickhaut HH; Galiatsatos P
    Nervenarzt; 1968 Dec; 39(12):552-6. PubMed ID: 5733572
    [No Abstract]   [Full Text] [Related]  

  • 50. [Therapeutic results with dimetracine in inhibited and in anxious-agitated forms of depression].
    Nowak H; Olbrich E
    Wien Klin Wochenschr; 1973 Feb; 85(8):125-8. PubMed ID: 4690440
    [No Abstract]   [Full Text] [Related]  

  • 51. [Successful treatment using high-dose amoxapine for a depressive patient].
    Shigemura J; Nomura S; Kuwahara T; Sanga M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):119-25. PubMed ID: 10495986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The multiple diagnoses of comorbid anxiety disorders and higher interpersonal sensitivity predict treatment-resistant depression.
    Mogi T; Yoshino A
    Asian J Psychiatr; 2017 Apr; 26():131-135. PubMed ID: 28483076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.
    Kulhan T; Marcincakova Husarova V; Ondrejka I; Farsky I; Nosalova G
    Neuro Endocrinol Lett; 2018 Feb; 38(8):579-585. PubMed ID: 29504736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Preliminary note on the action of thiothixen in psychoneurotic patients].
    Migliarese L
    Fracastoro; 1968; 61(2):187-90. PubMed ID: 5704051
    [No Abstract]   [Full Text] [Related]  

  • 55. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series.
    Schwartz TL
    Psychopharmacol Bull; 2002; 36(2):53-7. PubMed ID: 12397840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nefazodone for patients with chronic fatigue syndrome.
    Hickie I
    Aust N Z J Psychiatry; 1999 Apr; 33(2):278-80. PubMed ID: 10336228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between concurrent depression and anxiety and six-month outcome of addiction treatment.
    Charney DA; Palacios-Boix J; Negrete JC; Dobkin PL; Gill KJ
    Psychiatr Serv; 2005 Aug; 56(8):927-33. PubMed ID: 16088008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nefazodone overdose: a case report.
    Catalano G; Catalano MC; Tumarkin NB
    Clin Neuropharmacol; 1999; 22(1):63-5. PubMed ID: 10047937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole].
    Medvedev VE; Trosnova AP; Dobrovol'skiĭ AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(7):25-9. PubMed ID: 18379478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A use of Magne-B6 in the treatment of anxiety-depressive states in patients with epilepsy].
    Kalinin VV; Zheleznova EV; Rogacheva TA; Sokolova LV; Polianskiĭ DA; Zemlianaia AA; Nazmetdinova DM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(8):51-5. PubMed ID: 15554143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.